Financial News

Upbeat Trial Results For Geron

Geron Corp.’s (Nasdaq: GERN) myelofibrosis treatment imetelstat successfully treated patients in a Mayo Clinic study. Shares of the biopharmaceutical leaped $2.31 to $5.91.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback